Drug-eluting stents and acute myocardial infarction: A lethal combination or friends?

Table 2 Randomized controlled trials of second-generation drug eluting stents in ST elevated myocardial infarction

Study	Year	Primary endpoint	Design	Randomized ratio	Maximal length of follow-up	Stent comparisons (n)	Results of the primary endpoint
ZEST-AMI[38]	2009	Death, MI, and ischemia-driven TVR at 1 yr	Multicenter, safety study	1:1:1	1 yr	PES/SES/PC-ZES 328 (110/110/108)	No significant differences between stents
KOMER[39]	2011	Cardiac death, MI, ischemia-driven TLR at 1 yr	Multicenter, safety study	1:1:1	18 mo	PES/SES/PC-ZES 611 (202/204/205)	PC-ZES as safe as SES and PES
EXAMINATION[40,41]	2011	Death, MI, any revascularization at 1 yr	Multicenter, superiority	1:1	2 yr	CoCr-EES/BMS 1504 (751/747)	CoCr-EES superior to BMS
XAMI[42]	2012	Cardiac death, MI, TVR at 1 yr	Multicenter, noninferiority	2:1	1 yr	EES/SES 625 (404/221)	EES noninferior to SES
COMFORTABLE AMI[43]	2012	cardiac death, reinfarction, and TLR at 1 yr	Multicenter, superiority	1:1	1 yr	EES/BMS 1161 (575/582)	BES superior to BMS

MI: Myocardial infarction; TLR: Target lesion revascularization; CoCr-EES: Cobalt-chromium everolimus-eluting stents; PC-ZES: Phosphorylcholine polymer based zotarolimus-eluting stent; PES: Paclitaxel-eluting stents; SES: Sirolimus-eluting stents; TVR: Target vessel revascularization; BMS: Bare metal stent stents.